Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956440 | 1.00 | P2RY12 (0.41) | P2RY12MEN1KMT2ADPP4DPP8 | |
| SCHEMBL693694 | 0.93 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL694227 | 0.93 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL317073 | 0.91 | DPP4 (0.44) | P2RY12MEN1KMT2ADPP4DPP8 | |
| SCHEMBL317074 | 0.91 | DPP4 (0.44) | P2RY12MEN1KMT2ADPP4DPP8 | |
| Acetic Acid SCHEMBL317606 | 0.90 | P2RY12 (0.47) | P2RY12 | |
| SCHEMBL1143510 | 0.84 | TSHR (0.40) | P2RY12MEN1KMT2ADPP4DPP8 | |
| SCHEMBL1143508 | 0.84 | TSHR (0.40) | P2RY12MEN1KMT2ADPP4DPP8 | |
| SCHEMBL22910970 | 0.82 | DPP7 (0.39) | P2RY12MEN1KMT2ADPP4DPP8 | |
| SCHEMBL23893372 | 0.80 | DPP7 (0.41) | MEN1KMT2ADPP4DPP8NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | P2RY12 2/4885MEN1 2661/4885KMT2A 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.